Day: March 23, 2026

us corporate news

Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis

Minichart

March 23, 2026

Gyre Therapeutics Files New Drug Application for F351 (Hydro...

Continue Reading 0

us corporate news

Strategy Inc Announces Bitcoin Holdings Update and ATM Offering Results in March 2026

Minichart

March 23, 2026

Strategy Inc. 8-K Filing Analysis – March 23, 2026 Strat...

Continue Reading 0

us corporate news

Byrna Technologies Inc. Files Form 8-K and Releases March 2026 Investor Presentation on Business Update and Financial Information

Minichart

March 23, 2026

Byrna Technologies Inc. Files Updated Investor Presentation ...

Continue Reading 0

us corporate news

Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State

Minichart

March 23, 2026

Ensysce Biosciences, Inc. Files Certificate of Correction fo...

Continue Reading 0

us corporate news

NN, Inc. Targets Record Growth in 2026 with Focus on Automotive, Electrical Grid, and Data Center Markets

Minichart

March 23, 2026

NN, Inc. 2026 Roth Conference Investor Presentation - In-Dep...

Continue Reading 0

us corporate news

Okta, Inc. Files Form 8-K Announcing No Amendments, Securities Details, and Company Information – March 19, 2026

Minichart

March 23, 2026

Okta, Inc. Announces Departure of Board Member in Latest 8-K...

Continue Reading 0

us corporate news

Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1

Minichart

March 23, 2026

Aurinia Pharmaceuticals Announces Major Management Changes a...

Continue Reading 0

us corporate news

Liberty Live Holdings, Inc. Closes Exchange of 2.375% Exchangeable Senior Debentures Due 2053 – Indenture Details and Key Terms

Minichart

March 23, 2026

Liberty Live Holdings, Inc. Closes Exchange of Senior Debent...

Continue Reading 0

us corporate news

Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1

Minichart

March 23, 2026

Theriva Biologics Receives Positive FDA Feedback to Advance ...

Continue Reading 0

us corporate news

Tempest Therapeutics Announces $2 Million Private Placement and Securities Purchase Agreement with Institutional and Strategic Investors

Minichart

March 23, 2026

Tempest Therapeutics, Inc. Announces Securities Purchase Agr...

Continue Reading 0